Differential diagnosis of community-acquired pneumonia and lung damage in respiratory viral infections, including COVID-19

Q4 Medicine

Pulmonologiya Pub Date : 2022-12-30 DOI:10.18093/0869-0189-2022-4161

D. Strelkova, A. A. Irgiskin, S. Rachina

{"title":"Differential diagnosis of community-acquired pneumonia and lung damage in respiratory viral infections, including COVID-19","authors":"D. Strelkova, A. A. Irgiskin, S. Rachina","doi":"10.18093/0869-0189-2022-4161","DOIUrl":null,"url":null,"abstract":"With the development of the coronavirus pandemic and its decline, bacterial pathogens will again play a significant role in the epidemiology of community-acquired pneumonia (CAP). Numerous studies have already examined clinical, laboratory, and instrumental indicators that allow differential diagnosis between viral infection and bacterial pneumonia. The role of conventional (e.g., C-reactive protein, procalcitonin, leukocytes) and novel laboratory markers (e.g., MxA1 protein, progranulin, copeptin) was revealed. Differences in lung CT and ultrasound findings were noted. The aim of this publication is to present data on the differential diagnosis between pulmonary involvement in viral infections, including COVID-19 (COronaVIrus Disease 2019), and bacterial CAP. Conclusion. Despite numerous studies, distinguishing bacterial CAP from viral lung injury, including that associated with COVID-19 infection, without microbiologic testing is a challenging task that requires a combined assessment of clinical data, laboratory data, and modern imaging studies. Obviously, express testing will be of particular interest in this case.","PeriodicalId":37383,"journal":{"name":"Pulmonologiya","volume":"92 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18093/0869-0189-2022-4161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

With the development of the coronavirus pandemic and its decline, bacterial pathogens will again play a significant role in the epidemiology of community-acquired pneumonia (CAP). Numerous studies have already examined clinical, laboratory, and instrumental indicators that allow differential diagnosis between viral infection and bacterial pneumonia. The role of conventional (e.g., C-reactive protein, procalcitonin, leukocytes) and novel laboratory markers (e.g., MxA1 protein, progranulin, copeptin) was revealed. Differences in lung CT and ultrasound findings were noted. The aim of this publication is to present data on the differential diagnosis between pulmonary involvement in viral infections, including COVID-19 (COronaVIrus Disease 2019), and bacterial CAP. Conclusion. Despite numerous studies, distinguishing bacterial CAP from viral lung injury, including that associated with COVID-19 infection, without microbiologic testing is a challenging task that requires a combined assessment of clinical data, laboratory data, and modern imaging studies. Obviously, express testing will be of particular interest in this case.

查看原文本刊更多论文

包括COVID-19在内的呼吸道病毒感染中社区获得性肺炎和肺损伤的鉴别诊断

随着新冠肺炎疫情的发展和消退，细菌性病原体将再次在社区获得性肺炎(CAP)流行病学中发挥重要作用。许多研究已经检查了临床、实验室和仪器指标，可以区分病毒性感染和细菌性肺炎。揭示了常规(如c反应蛋白、降钙素原、白细胞)和新型实验室标志物(如MxA1蛋白、蛋白原、copeptin)的作用。注意肺部CT和超声表现的差异。本出版物的目的是提供关于病毒性感染(包括COVID-19(冠状病毒病2019))和细菌性CAP之间肺部受累的鉴别诊断数据。尽管进行了大量研究，但在没有微生物学检测的情况下区分细菌性CAP与病毒性肺损伤(包括与COVID-19感染相关的肺损伤)是一项具有挑战性的任务，需要对临床数据、实验室数据和现代影像学研究进行综合评估。显然，在这种情况下，表达测试将特别有趣。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonologiya Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The aim of this journal is to state a scientific position of the Russian Respiratory Society (RRS) on diagnosis and treatment of respiratory diseases based on recent evidence-based clinical trial publications and international consensuses. The most important tasks of the journal are: -improvement proficiency qualifications of respiratory specialists; -education in pulmonology; -prompt publication of original studies on diagnosis and treatment of respiratory diseases; -sharing clinical experience and information about pulmonology service organization in different regions of Russia; -information on current protocols, standards and recommendations of international respiratory societies; -discussion and consequent publication Russian consensus documents and announcement of RRS activities; -publication and comments of regulatory documents of Russian Ministry of Health; -historical review of Russian pulmonology development. The scientific concept of the journal includes publication of current evidence-based studies on respiratory medicine and their discussion with the participation of Russian and foreign experts and development of national consensus documents on respiratory medicine. Russian and foreign respiratory specialists including pneumologists, TB specialists, thoracic surgeons, allergists, clinical immunologists, pediatricians, oncologists, physiologists, and therapeutists are invited to publish article in the journal.